期刊文献+

临床药师对阿司匹林安全性干预研究 被引量:5

Clinical Pharmacists' Intervention Study on Safety of Aspirin
下载PDF
导出
摘要 目的:通过临床药师宣教,研究临床药师对药品不良反应的影响。方法:从高血压、糖尿病、冠心病、脑卒中、高血脂的患者中抽取服用阿司匹林者262例,制作《阿司匹林用药手册》及宣教幻灯片,向患者传播阿司匹林用药知识及减轻、减少药品不良反应措施。选取的患者在宣教、随访、讲课等干预前后,分别进行B超检查并测定出凝血时间、血常规、肝功能、肾功能。结果:干预前后胃肠道反应、出血倾向、血栓形成倾向、肝功能异常发生率降低显著,肾功能异常、神经系统反应、凝血障碍发生率也有所降低。临床药师干预前不良反应发生率约12.21%,干预后降低到3.82%。患者用药依从性从干预前的23.48%提升到干预后的69.05%。结论:临床药师可以减少、减轻药品不良反应,提高患者用药安全性和用药依从性。 OBJECTIVE: To study the effect of clinical pharmacists' intervention including propaganda and instruction on the occurrence of adverse drug reactions.METHODS: 262 patients with hypertension,diabetes,coronary heart disease,stroke or hyperlipemia treated with aspirin were sampled,and "Medication Manuals of Aspirin" and lantern slide for propaganda and instruction were made in order to spread the medication knowledge about aspirin among patients and instruct them how to reduce the adverse reactions of aspirin.Blooding time,clotting time,routine blood test,liver function and kidney function were measured before and after the implementation of the intervention measures including propaganda instruction,follow-up and lecture etc.RESULTS: After intervention,the incidences of gastrointestinal reactions,bleeding tendency,thrombophilia,abnormal liver function were reduced significantly,and the incidence rates of abnormal kidney function,nervous system reactions and coagulopathy reduced to some degree;and the incidence of adverse reactions reduced from 12.21% to 3.82% and patients' medication compliance rose from 23.48% to 69.05%.CONCLUSION: Clinical pharmacists' intervention is conducive to the reduction and mitigation of adverse drug reactions as well as the improvement of patients' medication safety and medication compliance.
出处 《中国医院用药评价与分析》 2010年第1期72-74,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 江苏省卫生厅医学科技发展基金临床药学科研项目(No.200703)
关键词 阿司匹林 安全性 干预 Aspirin Safety Intervention
  • 相关文献

参考文献11

二级参考文献58

  • 1郑书成,乔宝安,陈学风.阿斯匹林新用途与不良反应[J].中国新医药,2003,2(6):69-70. 被引量:5
  • 2胡大一,孙艺红.美国胸科医师协会抗栓和溶栓治疗指南简介(1)[J].中国医药导刊,2005,7(1):62-66. 被引量:11
  • 3Antithrombotic Trialists′ Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86.
  • 4Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.The SALT Collaborative Group.Lancet,1991,338:1345-1349.
  • 5European Stroke Prevention Study 2.Efficacy and safety data.J Neurol Sci,1997,151 Suppl:S1-S77.
  • 6Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.EAFT (European Atrial Fibrillation Trial) Study Group.Lancet,1993,342:1255-1262.
  • 7Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med,2005,352:1293-1304.
  • 8The International Stroke Trial (IST):a randomised trial of aspirin,subcutaneous heparin,both,or neither among 19435 patients with acute ischaemic stroke.International Stroke Trial Collaborative Group.Lancet,1997,349:1569-1581.
  • 9CAST:randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.CAST (Chinese Acute Stroke Trial) Collaborative Group.Lancet,1997,349:1641-1649.
  • 10Antithrombotic Trials, Collaboration. Prevention of death, myocardial infarction end stroke by antiplatelet therapy in high risk patients. BM J, 2002; 324;71 ~ 86.

共引文献366

同被引文献39

  • 1孙宜萍.老年患者的合理用药[J].世界临床药物,2005,26(9):523-527. 被引量:18
  • 2Gallup. Honesty~Ethics in professions[EB/OL ]. 2010-07- 09. http://www.gallup.com/poll/1654/honesty-ethics-prof- essions.aspx.
  • 3World Health Organization. World health statistics 2010: Part 2[EB/OL]. 2010-07-05. http://www.who.int/whosis/ whostat/2010/en/.
  • 4International Pharmaceutical Federation. 2009 FIP Global Pharmacy Workforce Report[EB/OL ]. 2010-06-24. http:// www.fio.or/hr.
  • 5卫生部信息统计中心.2010中国卫生统计年鉴[M].北京:中国协和医科大学出版社,2010..23.
  • 6U.S. Department of Labor. Occupational outlook handbo- ok. 2010--11 Edition. PharmacistsfEB/OL]. 2010-07-09. http://www.bls.gov/oco/ocosO79.htm#eamings.
  • 7Ministry of Health, Labour and Welfare. Physicians, den- tists and pharmacists workforce report (2008)[EB/OL]. 2010-06-25. http://www.mhlw.go.jp/toukei/saikin/hw/ish- i/08/index.html.
  • 8Knapp K. The national pharmacist workforce study[EB/ OL]. 2010-04-16. http://www.pharmaeymanpower.eom.
  • 9Kopp, B J, Mrsan M, Erstad BL, et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist[J]. Am J Health Syst Pharm,2007,64(23):2 483.
  • 10Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recom- mendations for clinical pharmacy services and staffing[J]. Pharmacotherapy, 2001,21 (2) : 129.

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部